Valacyclovir: Nursing Drug Guide, Renal Dosing & Hold Rules
Healthcare medication guide: Table 1 renal dose adjustment, hydration, and neurotoxicity prevention when the oral prodrug accumulates from dehydration, missed CrCl-based dosing, elderly vulnerability, or nephrotoxic co-therapy.
Valacyclovir (Valtrex) is an oral prodrug converted to acyclovir, which is renally cleared. Labeling reports acute renal failure and CNS effects (agitation, hallucinations, confusion, encephalopathy, seizures)—especially when patients receive higher-than-recommended doses for their creatinine clearance, are dehydrated, elderly, or on nephrotoxic drugs. The highest-stakes nursing failures are continuing the standard shingles or genital-herpes schedule without applying Table 1 when CrCl falls below 50 mL/min, and not correcting poor oral intake before the next dose. Verify CrCl at admission and during therapy, maintain hydration, monitor BMP and mental status, and hold plus escalate when creatinine rises or neuro symptoms appear.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every oral dose, confirm current creatinine clearance and that Table 1 adjustment is applied when CrCl is below 50 mL/min—especially for shingles (1 g TID becomes 1 g q12h at CrCl 30–49). Rising creatinine, oliguria, or new confusion on valacyclovir means hold the dose and request pharmacy renal interval adjustment before the next scheduled tablet.
Most common brand names
Valacyclovir is available as generic tablets and as the brand Valtrex (500 mg and 1 g film-coated tablets). An extemporaneous oral suspension (25 mg/mL or 50 mg/mL) may be prepared from 500 mg tablets for pediatric patients when a solid form is not appropriate per labeling.
Valacyclovir is the L-valine ester prodrug of acyclovir (Zovirax). Cross-hypersensitivity to valacyclovir, acyclovir, or product components contraindicates use of either agent per labeling.
Why we give it — Indications
Valacyclovir treats herpesvirus infections in approved adult and pediatric populations. Nurses most often administer it for shingles (herpes zoster), genital herpes, and cold sores (herpes labialis), with suppressive therapy also approved in HIV-1–infected adults meeting CD4 criteria per labeling.
| Use | Detail |
|---|---|
| Cold sores (herpes labialis) | Adults and pediatric patients ≥12 years. Initiate at earliest symptom (tingling, itching, burning). Efficacy when started after papule/vesicle/ulcer is not established. |
| Genital herpes | Initial episode, recurrent episodes, and chronic suppressive therapy in immunocompetent adults; suppressive therapy in HIV-1–infected adults with CD4 ≥100 cells/mm³. Not a cure—reduces episode duration and frequency. |
| Herpes zoster (shingles) | Immunocompetent adults. Initiate at earliest sign; most effective within 48 hours of rash onset per labeling. |
| Chickenpox (varicella) | Immunocompetent pediatric patients aged 2 to <18 years. Initiate within 24 hours of rash onset per labeling. |
| Limitations | Not established for immunocompromised patients except HIV suppressive therapy; not for peds <12 with cold sores, <18 with zoster/genital herpes, or neonatal suppressive therapy per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Valacyclovir is converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. Acyclovir is a synthetic purine nucleoside analogue active against HSV-1, HSV-2, and VZV. Viral thymidine kinase phosphorylates acyclovir; cellular enzymes form the triphosphate, which inhibits viral DNA polymerase and terminates the chain. Because acyclovir is renally excreted unchanged and can precipitate in tubules at high concentrations, nursing care must protect renal perfusion and apply Table 1 dose adjustment—not only antiviral coverage.
Oral bioavailability of valacyclovir to acyclovir is approximately 54.5%—substantially higher than oral acyclovir—so standard tablet doses deliver greater acyclovir exposure and make missed renal adjustment especially dangerous.
Dosing overview
Always verify the prescriber order against current prescribing information, indication, weight, and renal function. Apply Table 1 for all indications when creatinine clearance is below 50 mL/min/1.73 m². May give with or without food per labeling.
Renal adjustment — Table 1 (all adult indications)
| Indication / normal regimen (CrCl ≥50) | CrCl 30–49 | CrCl 10–29 | CrCl <10 |
|---|---|---|---|
| Cold sores: 2 g BID × 1 day | 1 g BID × 1 day | 500 mg BID × 1 day | 500 mg single dose |
| Genital herpes — initial: 1 g q12h | No reduction | 1 g q24h | 500 mg q24h |
| Genital herpes — recurrent: 500 mg q12h | No reduction | 500 mg q24h | 500 mg q24h |
| Suppressive — 1 g daily | No reduction | 500 mg q24h | 500 mg q24h |
| Suppressive — 500 mg daily (≤9 rec/year) | No reduction | 500 mg q48h | 500 mg q48h |
| HIV suppressive: 500 mg q12h | No reduction | 500 mg q24h | 500 mg q24h |
| Herpes zoster: 1 g q8h | 1 g q12h | 1 g q24h | 500 mg q24h |
On a small screen, swipe or scroll sideways to see the full table.
Hemodialysis: Give the recommended dose after hemodialysis. During HD, acyclovir half-life is approximately 4 hours; about one-third of body acyclovir is removed during a 4-hour session per labeling.
Peritoneal dialysis: Labeling states supplemental doses should not be required after CAPD or CAVHD.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for guidance on the next scheduled dose, especially when renal intervals are extended.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Conversion to acyclovir | First-pass intestinal/hepatic metabolism | Delivers higher acyclovir exposure than oral acyclovir—renal adjustment is non-optional when CrCl falls |
| Bioavailability to acyclovir | ~54.5% | Greater systemic acyclovir AUC increases renal and CNS toxicity risk if Table 1 is missed |
| Acyclovir half-life | 2.5–3.3 h (normal renal function) | Prolonged in renal impairment—extend interval per Table 1, do not assume standard TID/BID schedule |
| Elimination | Renally excreted as acyclovir (~42% renal clearance of apparent plasma clearance) | Rising creatinine or oliguria requires hold, hydration assessment, and Table 1 adjustment |
| Food effect | May give without regard to meals | Oral tablets or suspension per order; hydration matters more than meal timing |
| Probenecid / cimetidine | Increase acyclovir Cmax and AUC (pharmacology) | Flag to pharmacy; monitor creatinine and neuro symptoms more closely when co-administered |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review BMP/creatinine clearance, urine output, hydration status, and concurrent nephrotoxic drugs
- Confirm allergy history to valacyclovir, acyclovir, or components; verify indication and that Table 1 adjustment is applied when CrCl <50 mL/min
- Compare today’s creatinine to baseline during medication reconciliation—especially on admission and after contrast, NSAIDs, or dehydration
Contraindications
- Hypersensitivity to valacyclovir, acyclovir, or any component
Important warnings (labeling)
- Acute renal failure — elderly, renal disease, supratherapeutic dosing for CrCl, nephrotoxic co-therapy, inadequate hydration
- CNS adverse reactions — agitation, hallucinations, confusion, encephalopathy, seizures in adults and pediatrics with or without renal impairment
- TTP/HUS — reported at high doses (8 g/day) in advanced HIV and transplant trials; discontinue if consistent symptoms/labs
Interactions
Section 7 states no clinically significant interactions are known in patients with normal renal function. Pharmacology notes probenecid and cimetidine increase acyclovir levels by reducing renal clearance—coordinate with pharmacy when both are ordered, particularly if eGFR/CrCl is impaired.
Administration
Oral tablets: 500 mg or 1 g per order. May administer with or without food. Ensure adequate hydration before and during therapy per labeling precautions.
Oral suspension: Extemporaneous 25 mg/mL or 50 mg/mL suspension prepared from 500 mg tablets per USP-NF instructions. Shake well; refrigerate 2–8 °C; discard after 28 days. Use weight-based pediatric chickenpox dosing with maximum 1 g TID.
- Follow safe medication administration rights—right dose includes Table 1 renal adjustment
- Encourage oral fluids when safe; document intake and urine output during high-dose shingles courses
- Do not crush or split 1 g scored tablets unless pharmacy confirms—verify swallowing ability in elderly patients
Labeling warns acyclovir can precipitate in renal tubules when solubility (2.5 mg/mL in intratubular fluid) is exceeded—often with dehydration, missed Table 1 adjustment, or doses above recommendations for renal function. Oral valacyclovir is not an IV drug; the nursing lever is CrCl-verified dosing plus hydration.
Expected therapeutic response
- Shortened time to lesion healing and reduced new lesion formation in zoster and HSV when started early per trial labeling
- Decreased duration of pain and viral shedding in treated zoster when initiated within 48 hours of rash
- Improved chickenpox symptoms when started within 24 hours of rash in pediatric patients
- Stable or improving renal function and mental status while on therapy—any worsening requires reassessment before the next dose
Red flags — Stop and act
Renal failure and neurotoxicity can progress quickly when acyclovir accumulates from valacyclovir. Hold the dose and escalate immediately.
- Rising creatinine, elevated BUN, oliguria, or renal pain suggesting acute kidney injury
- Agitation, confusion, hallucinations, tremor, seizure, lethargy, or encephalopathy—especially in elderly or renally impaired patients
- Signs of TTP/HUS at high doses in immunocompromised patients (labeling warning—can be fatal)
- Serious rash, angioedema, or anaphylaxis
- Continued full-dose schedule when CrCl has fallen below Table 1 thresholds without pharmacy adjustment
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Headache | >10% adults; most common peds AE | Supportive care; differentiate from neurotoxicity if confusion or tremor co-occur |
| Nausea, abdominal pain | >10% adults per labeling | Supportive care; ensure hydration; assess renal function if GI symptoms accompany oliguria |
| Elevated creatinine / BUN, renal failure | Warnings — acute renal failure reported | Hold dose, hydrate, notify prescriber/pharmacy for Table 1 adjustment; trend BMP |
| CNS effects | Post-marketing; marked in elderly/renal impairment | Stop valacyclovir, monitor neuro status, notify prescriber urgently |
| TTP/HUS | High-dose trials in immunocompromised patients | Stop valacyclovir, urgent hematology evaluation |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose may cause acyclovir tubule precipitation with elevated BUN and creatinine and acute renal failure. CNS toxicity (agitation, confusion, seizure) may also occur.
Management
Supportive care per clinical status. In acute renal failure with anuria, the patient may benefit from hemodialysis until renal function is restored per labeling. No specific antidote is listed. Contact local poison control / toxicology services per facility protocol if overdose is suspected.
Look-alike / sound-alike and error prevention
- Valacyclovir vs acyclovir—prodrug vs active drug; doses are not interchangeable; cross-hypersensitivity contraindicates both
- Valacyclovir vs valganciclovir—sound-alike antivirals with different renal profiles; independent double-check
- Valtrex vs vancomycin—verify drug name on MAR during antiviral vs antibiotic orders
- 1 g TID shingles vs 500 mg BID recurrent genital—indication-specific regimens; wrong indication dose is a high-risk error
- Missed Table 1 adjustment—continuing 1 g TID when CrCl is 30–49 is a common preventable renal failure pathway
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Hydration | Encourage oral fluids when safe; poor intake plus TID shingles dosing accelerates renal injury per warnings |
| CrCl timing | Check BMP before starting and during therapy in elderly, CKD, or dehydrated patients |
| Table 1 | Shingles at CrCl 30–49: 1 g q12h (not TID); at 10–29: 1 g q24h; below 10: 500 mg q24h |
| Dialysis | Schedule dose after hemodialysis; half-life ~4 h during HD session |
| Commonly missed | Continuing standard TID after creatinine rise; no pharmacy consult when CrCl drops below 50 |
| Ask pharmacy when | Renal adjustment needed, probenecid/cimetidine interaction, suspension compounding, or hemodialysis timing |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment | Table 1 dose reduction required. Acute renal failure reported when doses exceed recommendations for CrCl. |
| Chronic kidney disease | Baseline reduced CrCl demands Table 1 from first dose; trend BMP during multi-day courses |
| Older adults | More likely to have reduced renal function and CNS adverse events; longer post-herpetic neuralgia duration in zoster trials. Dose-reduce per Table 1. |
| Dehydrated patients | Inadequate hydration increases tubule precipitation risk—correct volume status before continuing therapy |
| Immunocompromised (HIV suppressive) | Approved only for suppressive genital herpes with CD4 ≥100; TTP/HUS reported at very high doses in other populations |
| Pregnancy | Registry data show no major birth defect signal above general population; miscarriage data insufficient—use if benefit justifies risk |
| Lactation | Acyclovir in milk; ~0.6 mg/kg/day infant exposure with maternal 500 mg BID. LactMed: treatment of choice for herpes when indicated. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Creatinine, BUN, and urine output—especially during shingles (1 g TID) and when nephrotoxic drugs co-exist
- Mental status, tremor, agitation, or seizure activity (CNS toxicity risk with renal impairment)
- Hydration status and intake/output during oral therapy
- Lesion healing, pain, and symptom trend for the treated herpesvirus infection
Document
- Dose, route, indication, and verified Table 1 renal adjustment on MAR
- Creatinine clearance source and date when renal-modified schedule used
- Intake/output and hydration teaching provided
Patient teaching
- Drink adequate fluids unless fluid-restricted—hydration protects the kidneys while acyclovir is cleared renally
- Complete the full prescribed course even if lesions improve; do not share medication
- For genital herpes: valacyclovir is not a cure; safer sex practices remain important during suppressive therapy
- Report decreased urination, flank pain, confusion, tremor, severe rash, or breathing difficulty immediately
- Breastfeeding patients: discuss risks and benefits with the prescriber; LactMed supports use when herpes treatment is indicated
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to valacyclovir, acyclovir, or components
- Rising creatinine, oliguria, or acute kidney injury while on valacyclovir
- Order lacks required Table 1 adjustment when CrCl is below 50 mL/min (or meets lower thresholds for specific regimens)
- New neurotoxicity symptoms (confusion, agitation, tremor, seizure, lethargy)
- Significant dehydration or inability to maintain hydration until plan clarified
- Suspected overdose or double-dose administration
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Valacyclovir is often started in outpatient clinics, ED discharge, or med-surg units for shingles—exactly when elderly patients with borderline CrCl and poor oral intake may receive full 1 g TID without Table 1 review. Build renal verification into the oral medication pass.
1. Check-before-you-give protocol
- Right patient, dose, route, time—and right Table 1 creatinine clearance adjustment
- Confirm indication matches regimen (shingles TID vs genital BID vs cold-sore 1-day course)
- Assess hydration status and nephrotoxic drug overlap on MAR
- Compare today’s creatinine to baseline before starting or continuing multi-day therapy
2. High-alert and safety badge
Not ISMP high-alert — renal dose adjustment criticalValacyclovir is not on the ISMP high-alert list, but missed Table 1 adjustment plus dehydration causes preventable acute renal failure and neurotoxicity. Treat CrCl verification with the same rigor as high-alert renal drugs.
3. Clinical workflow: hold and question rules
- If creatinine rises ≥0.3–0.5 mg/dL from baseline or urine output drops, hold the next dose pending pharmacy Table 1 adjustment
- If probenecid or new nephrotoxic therapy is added, notify pharmacy before the next valacyclovir dose
- Any confusion or tremor on valacyclovir triggers neuro assessment and prescriber notification—do not restart until cleared
4. Critical teach-back questions
- “Why is it important to drink fluids while taking valacyclovir?” (Patient should link fluids to protecting the kidneys while the drug converts to acyclovir and is cleared renally.)
- “What symptoms should you report right away?” (Patient should name decreased urination, confusion, severe rash, or trouble breathing.)
5. Care coordination
Pharmacist: Table 1 renal dose adjustment, probenecid/cimetidine interaction, hemodialysis timing, suspension compounding
Prescriber / nephrology: Rising creatinine, oliguria, persistent neuro symptoms, or need to stop therapy when renal function declines
🧠 Quick mental checklist
- What is this patient’s creatinine clearance and most recent creatinine trend?
- Has Table 1 been applied if CrCl is below 50 mL/min?
- Is the patient adequately hydrated—and are nephrotoxic drugs on the MAR?
- Does the indication match the dose (shingles TID vs genital BID vs 1-day cold-sore course)?
- Any new confusion, tremor, seizure, or decreased urine output since the last dose?
Valacyclovir NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for oral valacyclovir renal safety using a tabbed outpatient-to-inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), creatinine trend interpretation, documentation cloze, ordered response, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Valacyclovir (Valtrex) 1 g PO TID for shingles — given 0800, 1400; next due 2000
- Ibuprofen 400 mg PO PRN pain — last given 1500
- Acetaminophen 650 mg PO PRN — available, not given today
- Pharmacy note: no Table 1 adjustment entered despite CrCl 35 mL/min on admission
- Admission: creatinine 1.1 mg/dL; BUN 19 mg/dL; eGFR 52 mL/min/1.73 m²; CrCl estimated 35 mL/min
- Today (day 2, 1700): creatinine 1.9 mg/dL; BUN 32 mg/dL; eGFR 28 mL/min/1.73 m²
- Repeat BMP ordered; pharmacy renal dose review pending
- BP 118/68 mmHg; HR 88/min; RR 16/min; SpO₂ 97% on room air; temp 37.1 °C
- Weight 62 kg; mucous membranes dry; skin turgor reduced
- 24 h oral intake ~480 mL; urine output ~520 mL (≈22 mL/h average)
- Orthostatic BP: lying 118/68; standing 102/60 with mild dizziness
- 78-year-old admitted for shingles pain; valacyclovir started yesterday at standard 1 g TID
- Poor oral intake × 2 days; refuses most meals; reports dry mouth
- 1700: alert; oriented ×3 with mild confusion when asked about time; denies flank pain
- Teaching gap: patient unaware valacyclovir dose should change when kidneys are weak
Answer key & rationale
Frequently asked questions
How should nurses adjust valacyclovir when creatinine clearance falls?
Use Table 1 from Valtrex labeling for all indications. For shingles at CrCl 30–49 mL/min, reduce from 1 g every 8 hours to 1 g every 12 hours; at CrCl 10–29, give 1 g every 24 hours; at CrCl below 10, give 500 mg every 24 hours. Hemodialysis patients should receive the recommended dose after dialysis.
Why is hydration important with oral valacyclovir?
Valacyclovir converts to acyclovir, which is renally cleared. Labeling warns that acyclovir can precipitate in renal tubules when solubility is exceeded—especially with dehydration, elderly patients, or doses above Table 1 recommendations. Adequate hydration reduces acute renal failure risk.
When should a nurse hold valacyclovir and contact the prescriber or pharmacist?
Hold for hypersensitivity to valacyclovir, acyclovir, or components; rising creatinine or oliguria; orders that omit required Table 1 adjustment when CrCl is below 50 mL/min; significant dehydration; new CNS symptoms such as confusion, agitation, tremor, or seizure; or suspected overdose.
Is valacyclovir safe during pregnancy and breastfeeding?
Registry data have not identified a major birth defect risk above the general population, but miscarriage data are insufficient. LactMed lists valacyclovir as a treatment of choice for herpes during breastfeeding when indicated; acyclovir appears in milk with estimated infant exposure about 0.6 mg/kg/day when the mother takes 500 mg twice daily.
What are signs of valacyclovir overdose or toxicity?
Overdose can cause tubule precipitation with elevated BUN and creatinine, acute renal failure, and CNS effects including agitation, confusion, and seizure. Management is supportive; hemodialysis may benefit patients with acute renal failure and anuria. No specific antidote is listed.
Does valacyclovir have clinically significant drug interactions?
Section 7 of labeling states no clinically significant interactions are known in patients with normal renal function. Pharmacology notes probenecid and cimetidine increase acyclovir levels by reducing renal clearance—coordinate with pharmacy when both are ordered, especially if renal function is impaired.
References
- U.S. National Library of Medicine. Valacyclovir hydrochloride tablet — Full prescribing information (Valtrex). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f338cd7-3520-337b-e063-6294a90aa45d
- Drugs and Lactation Database (LactMed). Valacyclovir. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501262/
- U.S. National Library of Medicine. Valacyclovir — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a695010.html
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.accessdata.fda.gov/scripts/medwatch/
- National Library of Medicine. Drugs and Lactation Database (LactMed) — About and peer review. NCBI Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK501922/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.